Kai Brown Email & Phone Number

South San Francisco, California, US

New York, NY, US

Retained by Series A venture backed biotech to develop and drive implementation of corporate and business development strategy. Manage in/out licensing while positioning startup for continued growth and expansion, steering portfolio planning, and supporting fundraising.

Lawrence Township, NJ, US

Devised successful pipeline product development strategies by conducting comprehensive opportunity assessments and recommending actionable steps to drive revenue. Directed asset positioning, indication selection, and prioritization of potential assets to propel the $14B BMS / Myokardia integration.

Brisbane, California, US

Joined this team to drive pipeline strategy and market development initiatives across 6 early-stage development programs. Myokardia acquired by Bristol Myers Squibb in 2020.

South San Francisco, CA, US

Led the strategy and launch of the company's key value driver in the Alexion Pharma acquisition. Spearheaded franchise expansion playbook that identified high value segments and articulated new strategic messaging platform. Built a high-performing team responsible for marketing growth initiatives. Portola Pharma acquired by Alexion Pharmaceuticals..

New York, NY, US

Selected as pipeline strategy lead across 6 early-stage oncology and non-oncology teams. Enhanced the commercial viability for Talazoparib – accounting for 30% of Pfizer’s $14B acquisition – by creating PARP inhibition scientific messaging, differentiation strategy, and positioning platform. Medivation acquired by Pfizer.

Led PROCYSBI commercial strategy and executed multiple HCP and patient programs / promotions that addressed strategic imperatives. Supported label expansion through development of promotional messaging platform and execution of multi-channel communication plan. Raptor acquired by Horizon Pharma.

Second commercial hire responsible for primary and secondary market research, competitive intelligence, and forecasting to drive commercial strategy across various orphan diseases. Responsible for search and evaluation business development efforts. Led cross functional team's preparation for global product launch.

Led and managed Procysbi launch analytics and market research initiatives to ensure a successful product launch in nephropathic cystinosis.

San Rafael, CA, US

Licensing professional responsible for executing corporate development initiatives, leading search and evaluation, and crafting opportunity assessments in the orphan / rare disease space.

Managed and closed a broad range of strategic transactions from research collaboration deals to commercial supply agreements.

Dublin, IE

Responsible for search and evaluation and in/out licensing efforts. Executed out-licensing deal. Managed cross-functional evaluation teams, due diligence, conducted market research and financial analyses, negotiated deal terms.

South San Francisco, California, US

Analyzed the drug delivery space to identify and recommend potential in-licensing candidates to support the protein therapeutic portfolio. Negotiated a research technology deal that resulted in the expansion of research tools necessary for drug discovery.

South San Francisco, California, US

Conducted primary market research to develop strategic recommendations for a Direct to Patient marketing initiative.

Rahway, New Jersey, US

Proven scientist skilled in assay development in various therapeutic areas, including Immunology, Atherosclerosis, Endocrinology and Neurology. Responsible for elucidating complex biological mechanisms of action and leading drug discovery efforts resulting in nearly 10 clinical candidates.

Mba

Masters, Biotechnology

Ba, Psychology, Biology